← All trials
NCT04445844
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 13, 2020
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Jun 24, 2020
- Last posted
- Jul 22, 2020
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rutgers UniversityLead sponsor
- IncyteCollaborator
- Oncolytics BiotechCollaborator
- National Cancer Institute (NCI)Collaborator
- Rutgers UniversityOverall official - principal investigator
- Rutgers UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.